Comparison of complications and shocks in paediatric and young transvenous and subcutaneous implantable cardioverter-defibrillator patients

被引:17
|
作者
Quast, A. B. E. [1 ]
Brouwer, T. F. [1 ]
Kooiman, K. M. [1 ]
van Dessel, P. F. H. M. [1 ]
Blom, N. A. [2 ]
Wilde, A. A. M. [1 ]
Knops, R. E. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Cardiovasc Sci, Dept Clin & Expt Cardiol, Amsterdam UMC,Heart Ctr, Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Paediat Cardiol, Amsterdam UMC, Amsterdam, Netherlands
关键词
Implantable cardioverter-defibrillator; Device-related complications; Inappropriate therapy; Paediatric; Young; Subcutaneous ICD; CLINICAL-EXPERIENCE; CHILDREN; ADULTS;
D O I
10.1007/s12471-018-1186-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundYoung implantable cardioverter-defibrillator (ICD) patients are prone to complications and inappropriate shocks (IAS). The subcutaneous ICD (S-ICD) may avoid lead-related complications. This study aims to describe the incidence and nature of device-related complications in young transvenous ICD (TV-ICD) and S-ICD patients.MethodsSingle-chamber TV-ICD and S-ICD patients up to and including the age of 25years implanted between 2002 and 2015 were retrospectively analysed. Complications were defined as device-related complications requiring surgical intervention. IAS were defined as shocks for anything other than ventricular tachycardia or ventricular fibrillation. Follow-up data were collected 5years post-implantation. Kaplan-Meier estimates for complications at 5-year follow-up were calculated with acorresponding 95% confidence interval.ResultsEighty-one patients (46TV-ICD, 35S-ICD) were included (median age 19.0 (IQR 16.0-23.0) and 16.5 (IQR 13.0-20.2) years respectively). Median follow-up was 60 and 40months respectively. All-cause complication rate was 34% in the TV-ICD group and 25% in the S-ICD group (p=0.64). TV-ICD patients had more lead complications: 23% (10-36%) versus 0% (p=0.02). The rate of infections did not differ between TV-ICD and S-ICD: 2% (0-6%) versus 10% (0-21%) (p=0.15). No systemic infections occurred in the S-ICD patients. The rates of IAS were similar, TV-ICD 22% (9-35%) versus S-ICD 14% (0-30%) (p=0.40), as were those for appropriate shocks: 25% (11-39%) versus 27% (6-48%) (p=0.92).ConclusionThe rates of all-cause complications in this cohort were equal, though the nature of the complications differed. S-ICD patients did not suffer lead failures or systemic infections. An era effect is present between the two groups.
引用
收藏
页码:612 / 619
页数:8
相关论文
共 50 条
  • [21] Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis
    Koman, Eduard
    Gupta, Ashwani
    Subzposh, Faiz
    Saltzman, Heath
    Kutalek, Steven P.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2016, 45 (02) : 219 - 223
  • [22] Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy
    Francia, Pietro
    Adduci, Carmen
    Palano, Francesca
    Semprini, Lorenzo
    Serdoz, Andrea
    Montesanti, Dalma
    Santini, Daria
    Musumeci, Beatrice
    Salvati, Adriano
    Volpe, Massimo
    Autore, Camillo
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2015, 26 (08) : 893 - 899
  • [23] Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis
    Eduard Koman
    Ashwani Gupta
    Faiz Subzposh
    Heath Saltzman
    Steven P Kutalek
    Journal of Interventional Cardiac Electrophysiology, 2016, 45 : 219 - 223
  • [24] Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making
    Leo, Milena
    Sharp, Alexander J.
    Gala, Andre Briosa E.
    Pope, Michael T. B.
    Betts, Timothy R.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2022,
  • [25] Incidence of Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Heart Failure Treated With Combined Cardiac Resynchronization Plus Implantable Cardioverter-Defibrillator Therapy Versus Implantable Cardioverter-Defibrillator Therapy
    Desai, Harit
    Aronow, Wilbert S.
    Ahn, Chul
    Tsai, Fausan S.
    Lai, Hoang M.
    Gandhi, Kaushang
    Amin, Harshad
    Frishman, William H.
    Kalapatapu, Kumar
    Cohen, Martin
    Sorbera, Carmine
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 15 (01) : 37 - 40
  • [26] Contemporary trends and factors associated with use of subcutaneous versus transvenous implantable cardioverter-defibrillator therapy
    Shatla, Islam
    Mehta, Nikhil
    Kennedy, Kevin F.
    Elkaryoni, Ahmed
    Wimmer, Alan P.
    EUROPACE, 2024, 26 (07):
  • [27] Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: Implications for management
    Kooiman, Kirsten M.
    Knops, Reinoud E.
    Nordkamp, Louise Olde
    Wilde, Arthur A. M.
    de Groot, Joris R.
    HEART RHYTHM, 2014, 11 (03) : 426 - 434
  • [28] Subcutaneous implantable cardioverter-defibrillator (S-ICD)
    Lobodzinski, S. Suave
    CARDIOLOGY JOURNAL, 2011, 18 (03) : 326 - 331
  • [29] The Subcutaneous Implantable Cardioverter-Defibrillator When Less Is More
    Curtis, Anne B.
    Beck, Hiroko
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (16) : 1616 - 1618
  • [30] First case of subcutaneous implantable cardioverter-defibrillator extrusion
    Santarpia, Giuseppe
    Polimeni, Alberto
    De Rosa, Salvatore
    Sabatino, Jolanda
    Curcio, Antonio
    Indolfi, Ciro
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 192 : 19 - 20